JPMorgan initiated coverage of Amrize (AMRZ) with an Overweight rating and $57 price target representing 13% upside potential. The firm says the company’s “robust” EBITDA growth prospects and “strong” free cash flow conversion rate of over 50% make it an attractive investment. Amrize has a proven track record on acquisitions, which opens opportunities for capital allocation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ: